Search
Hydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.
Tolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Danaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnThe use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnIt is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Categories: Compounds used in a research, industrial, or household settingFlosequinan
go.drugbank.com/drugs/DB13228ApprovedWithdrawnFlosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Categories: Vasodilators Used in Cardiac DiseasesImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] The Val30Met variant is the most prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and Japan. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.